Cargando…

Natural Killer Cell-Based Immunotherapy against Glioblastoma

Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morimoto, Takayuki, Nakazawa, Tsutomu, Maeoka, Ryosuke, Nakagawa, Ichiro, Tsujimura, Takahiro, Matsuda, Ryosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/ https://www.ncbi.nlm.nih.gov/pubmed/36768432 http://dx.doi.org/10.3390/ijms24032111

Ejemplares similares

Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors
por: Nakazawa, Tsutomu, et al.
Publicado: (2022)

CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
por: Nakazawa, Tsutomu, et al.
Publicado: (2023)

Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors
por: Shida, Yoichi, et al.
Publicado: (2021)

Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom
por: Maeoka, Ryosuke, et al.
Publicado: (2023)

An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood
por: Nakazawa, Tsutomu, et al.
Publicado: (2023)

Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent Stem Cell Lysate to Induce Cytotoxic T Lymphocytes against HLA-A33-Matched Cancer Cells
por: Nakazawa, Tsutomu, et al.
Publicado: (2022)

CRISPR-Cas9–Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells
por: Morimoto, Takayuki, et al.
Publicado: (2021)

Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids
por: Morimoto, Takayuki, et al.
Publicado: (2021)

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro
por: Tanaka, Yoshitaka, et al.
Publicado: (2019)

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report
por: Morimoto, Takayuki, et al.
Publicado: (2022)

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
por: Nakazawa, Tsutomu, et al.
Publicado: (2020)

STMO-15 THE CLINICAL IMPACT OF VENTRICULAR OPENING IN THE IMPLANTATION OF BCNU WAFERS FOR MALIGNANT GLIOMA
por: Matsuda, Ryosuke, et al.
Publicado: (2022)

Natural killer cell immunotherapy in glioblastoma
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Overlapping Stents with Coil Sandwich for Ruptured Blood-blister Aneurysm in a Patient with Ipsilateral Persistent Primitive Trigeminal Artery: A Case Report and Review of Literature
por: Maeoka, Ryosuke, et al.
Publicado: (2019)

Staged strategy using a transcarotid approach for acute tandem occlusions with left common carotid artery origin steno-occlusive lesion
por: Maeoka, Ryosuke, et al.
Publicado: (2021)

Mechanical thrombectomy in acute stroke for superior limb of the fenestration of the middle cerebral artery
por: Hosokawa, Makoto, et al.
Publicado: (2022)

A case of recurrent cavernous sinus dural arteriovenous fistula arising after superselective shunt occlusion and detected by venous arterial spin labeling
por: Sunada, Hiromu, et al.
Publicado: (2021)

Decline in the Incidence of Chronic Subdural Hematoma During the Coronavirus Disease 2019 Pandemic: A Retrospective Single-Center Descriptive Study
por: Maeoka, Ryosuke, et al.
Publicado: (2022)

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
por: Lupo, Kyle B., et al.
Publicado: (2020)

Natural Killer Cells and Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2023)

Stent-assisted coil embolization of unruptured vertebral artery dissecting aneurysms with the low-profile visualized intraluminal support stent, with five techniques: Technical note and case report
por: Maeoka, Ryosuke, et al.
Publicado: (2019)

Extensive Roles and Technical Advances of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
por: NAKAGAWA, Ichiro, et al.
Publicado: (2023)

False-positive inflammatory change mimicking glioblastoma multiforme under 5-aminolevulinic acid-guided surgery: A case report
por: Omoto, Koji, et al.
Publicado: (2018)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Natural killer cells in tumor immunotherapy
por: Wang, Dongyao, et al.
Publicado: (2023)

Advanced T and Natural Killer Cell Therapy for Glioblastoma
por: Yoon, Wan-Soo, et al.
Publicado: (2023)

Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
por: Wang, Minjie, et al.
Publicado: (2022)

Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro
por: Sivonen, Minna, et al.
Publicado: (2023)

In vitro Natural Killer Cell Immunotherapy for Medulloblastoma
por: Fernández, Lucia, et al.
Publicado: (2013)

Natural Killer Cells: Angels and Devils for Immunotherapy
por: Martín-Antonio, Beatriz, et al.
Publicado: (2017)

Modeling Natural Killer Cell Targeted Immunotherapies
por: Lopez-Lastra, Silvia, et al.
Publicado: (2017)

Natural Killer Cells in Immunotherapy: Are We Nearly There?
por: Bachiller, Mireia, et al.
Publicado: (2020)

Targeting Natural Killer Cells for Tumor Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Natural Killer Cell-Mediated Immunotherapy for Leukemia
por: Allison, Michaela, et al.
Publicado: (2022)

Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer
por: Zhao, Xiaoyan, et al.
Publicado: (2020)

Natural killer cell-based immunotherapy for acute myeloid leukemia
por: Xu, Jing, et al.
Publicado: (2020)

Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy
por: Murugan, Dhanashree, et al.
Publicado: (2022)

Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
por: Hwang, Sohyun, et al.
Publicado: (2023)

Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
por: Lee, Se Jeong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_evt8ei2v4v00c9e96mtof9vnfi